SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 95.54 |
| Enterprise Value ($M) | 52.52 |
| Book Value ($M) | 155.52 |
| Book Value / Share | 3.86 |
| Price / Book | 0.61 |
| NCAV ($M) | 133.22 |
| NCAV / Share | 3.30 |
| Price / NCAV | 0.72 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.03 |
| Return on Assets (ROA) | 0.02 |
| Return on Equity (ROE) | 0.03 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 27.08 |
| Current Ratio | 27.08 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 142.77 |
| Assets | 165.08 |
| Liabilities | 9.56 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | BML Investment Partners, L.P. | 5.00 | ||
| 13D | Kidron Nadav | 5.70 | 74.47 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 14,786 | 94,066 | 15.72 | |
| 22,635 | 167,122 | 13.54 | |
| 11,554 | 170,310 | 6.78 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ONCY – Oncolytics Biotech Inc. | ONVO – Organovo Holdings, Inc. |
| ORGO – Organogenesis Holdings Inc. | OTLK – Outlook Therapeutics, Inc. |
| PALI – Palisade Bio, Inc. |
Financial data and stock pages provided by
Fintel.io